KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Non-Current Deffered Revenue (2018 - 2025)

Historic Non-Current Deffered Revenue for Adaptive Biotechnologies (ADPT) over the last 8 years, with Q3 2025 value amounting to $1.2 million.

  • Adaptive Biotechnologies' Non-Current Deffered Revenue fell 9632.1% to $1.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 million, marking a year-over-year decrease of 9632.1%. This contributed to the annual value of $27.3 million for FY2024, which is 3915.12% down from last year.
  • Adaptive Biotechnologies' Non-Current Deffered Revenue amounted to $1.2 million in Q3 2025, which was down 9632.1% from $20.0 million recorded in Q2 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Non-Current Deffered Revenue peaked at $144.4 million during Q1 2021, and registered a low of $1.2 million during Q3 2025.
  • Over the past 5 years, Adaptive Biotechnologies' median Non-Current Deffered Revenue value was $50.9 million (recorded in 2023), while the average stood at $60.1 million.
  • As far as peak fluctuations go, Adaptive Biotechnologies' Non-Current Deffered Revenue crashed by 1808.27% in 2024, and later crashed by 9632.1% in 2025.
  • Over the past 5 years, Adaptive Biotechnologies' Non-Current Deffered Revenue (Quarter) stood at $98.8 million in 2021, then crashed by 40.66% to $58.6 million in 2022, then decreased by 23.56% to $44.8 million in 2023, then tumbled by 39.15% to $27.3 million in 2024, then crashed by 95.58% to $1.2 million in 2025.
  • Its last three reported values are $1.2 million in Q3 2025, $20.0 million for Q2 2025, and $24.8 million during Q1 2025.